![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Prediction of Renal OAT1 and OAT3 Inhibition by Cabotegravir Using PBPK Modelling
|
|
|
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
Kunal S. Taskar,1 Aarti Patel,1 Simon J. Cozens,1 Helen Tracey,1 Susan Ford,2 Kelong Han,2 William Spreen,3 Mark Baker,4 Parul Patel3
1GlaxoSmithKline, Ware, UK; 2GlaxoSmithKline, Research Triangle Park, NC, USA; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4ViiV Healthcare, Nyon, Switzerland
![0318191](../images/031819/031819-6/0318191.gif)
![0318192](../images/031819/031819-6/0318192.gif)
![0318193](../images/031819/031819-6/0318193.gif)
![0318194](../images/031819/031819-6/0318194.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|